If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysgeusia been reported in patients taking Mounjaro® (tirzepatide)?
In the SURPASS-1 and -5 studies in adults with type 2 diabetes, 0.1% of patients treated with tirzepatide experienced dysgeusia, and no patients treated with placebo experienced dysgeusia.
See important safety information, including boxed warning, in the attached prescribing information.
Dysgeusia
Dysgeusia is a condition that changes a person’s sense of taste, making everything taste sweet, sour, bitter, or metallic.1
In 2 studies comparing tirzepatide to placebo in adults with type 2 diabetes (SURPASS-1 and SURPASS-5), dysgeusia was reported by 0.1% of patients treated with tirzepatide and 0% of patients receiving placebo.2
Enclosed Prescribing Information
References
1Dysgeusia. Boston Medical Center. Updated April 2020. Accessed November 13, 2024. https://www.bmc.org/patient-care/conditions-we-treat/db/dysgeusia
2Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 04, 2024